
Immix Biopharma, Inc.: financial statements
Price
$6.96
November 20, 2026Market cap $583M
What Ploutos Investor adds for Immix Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Operating income
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Operating income | -$16M | -$23M | -$30M | |
| Net income | -$15M | -$22M | -$29M | |
| Earnings per share | -$0.89 | -$0.76 | -$0.89 | |
| Earnings per share, basic | -$0.89 | -$0.76 | -$0.89 |
Financial statements
IMMX's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$1.1M
Finance leases
–
- Lease cost for the year
- $204.6K
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
-0.1%
The company paid -0.1% in tax on its profit, 21.1 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Tax credits
+8.5 pts
Change in valuation allowance
-24.1 pts
Non-deductible expenses
-5.3 pts
Foreign losses not benefited
-0.2 pts
Effective rate
-0.1%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.
Effective tax rate by year
The tax rate IMMX paid on its profit, from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Immix Biopharma's filings show?
These are Immix Biopharma's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does IMMX have?
On December 31, 2025 Immix Biopharma had total assets of $105M, debt of – and shareholders' equity of $94M.
How much free cash flow does IMMX have?
In fiscal 2025 Immix Biopharma had cash from operations of -$24M and spent $732.9K on capital expenditure, leaving -$25M of free cash flow.
Where are the figures from?
From Immix Biopharma, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.